Novartis Delivers Strong Phase III Results for Fabhalta, Vanrafia, and Zigakibart, Boosting Investor Confidence
Novartis unveils Phase‑III success for Fabhalta and Vanrafia, showing significant proteinuria and BP reductions while preserving kidney function—boosting investor confidence and reshaping nephrology treatment.
4 minutes to read









